Latham & Watkins Advises Bluejay Therapeutics in US$620 Million+ Acquisition by Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. Under the terms of the definitive agreement, Mirum has agreed to acquire all outstanding shares of Bluejay for US$250 million in cash and US$370 million in Mirum common stock, plus potential tiered sales-based milestone payments of up to US$200 million in cash. The Mirum common stock issued to the Bluejay security holders at closing will be priced at US$71.2085 per share. The transaction with Bluejay has been approved by the Boards of Directors of both companies and is expected to close in the first quarter of 2026, subject to regulatory approval and other customary closing conditions.

Latham & Watkins LLP represents Bluejay Therapeutics in the transaction with a corporate deal team led by Bay Area partner Mark Roeder and New York partner Ian Nussbaum, with associates Andrew Forgy, Cristina Lombardi, Jamie Reinah, Rheem Brooks, and assistance from Max Siegel. Advice was also provided on corporate matters by associate Gregory Van Buiten; benefits matters by Bay Area partner Jay Metz, with associate Mary Daniel Morgan; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Washington, D.C. counsel Chad Jennings, with associate Evan Miller; on healthcare matters by Bay Area partner Betty Pang; on antitrust matters by Bay Area partner Joshua Holian and Washington, D.C. partner Patrick English, with assistance from Aimilia Kechagia; on intellectual property matters by San Diego counsel Robert Yeh, with associate Patrick Chew; on tax matters by Bay Area partner Katharine Moir, with associate Ted Gkoo; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Chad Leiper; and on labor and employment matters by Chicago counsel Laura Waller, with associate Jenny Bobbitt.